Suppr超能文献

维拉帕米的处置——磺吡酮和西咪替丁的影响。

Verapamil disposition--effects of sulphinpyrazone and cimetidine.

作者信息

Wing L M, Miners J O, Lillywhite K J

出版信息

Br J Clin Pharmacol. 1985 Mar;19(3):385-91. doi: 10.1111/j.1365-2125.1985.tb02658.x.

Abstract

The effects of separate 7 day pretreatments with sulphinpyrazone (800 mg daily) and cimetidine (1 g daily) on the disposition of (+/-)-verapamil have been examined in eight healthy volunteers (four male, four female). Each subject received single oral (80 mg) and intravenous (0.15 mg/kg) doses of verapamil on different occasions before and after each pretreatment. Following sulphinpyrazone pretreatment, verapamil apparent oral plasma clearance (CLpo) increased from 4.27 to 13.77 l h-1 kg-1 (s.e. mean 0.51--ANOVA) (P less than 0.001); CL increased from 1.05 to 1.20 l h-1 kg-1 (s.e. mean 0.05) (P less than 0.05) and Fpo decreased from 27 to 10% administered dose (s.e. mean 2) (P less than 0.001). Vss and t1/2,z were unchanged. There was no sex difference for any dispositional parameter in the control phase, but the increase in CLpo following sulphinpyrazone pretreatment was more marked in males (4.04 to 17.33 l h-1 kg-1) than in females (4.49 to 10.21 l h-1 kg-1) (s.e. mean 0.72) (P less than 0.01). There was no significant change in any verapamil disposition parameter following cimetidine pretreatment. Verapamil unbound fraction in plasma was 0.157 (s.e. mean 0.001, n = 40). There was no alteration in verapamil plasma protein binding associated with increasing verapamil concentration (25-250 micrograms l-1) or addition of sulphinpyrazone (50-500 mg l-1) or cimetidine (0.5-5 mg l-1). The results suggest that sulphinpyrazone induces the metabolic clearance of (+/-)-verapamil with a sex difference in the response.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在8名健康志愿者(4名男性,4名女性)中研究了分别用磺吡酮(每日800毫克)和西咪替丁(每日1克)进行7天预处理对(±)-维拉帕米处置的影响。在每次预处理前后的不同时间,每位受试者均接受了单次口服(80毫克)和静脉注射(0.15毫克/千克)剂量的维拉帕米。磺吡酮预处理后,维拉帕米的表观口服血浆清除率(CLpo)从4.27升/小时·千克增加至13.77升/小时·千克(标准误均值0.51——方差分析)(P<0.001);CL从1.05升/小时·千克增加至1.20升/小时·千克(标准误均值0.05)(P<0.05),Fpo从给药剂量的27%降至10%(标准误均值2)(P<0.001)。稳态分布容积(Vss)和终末消除半衰期(t1/2,z)未改变。在对照期,任何处置参数均无性别差异,但磺吡酮预处理后CLpo的增加在男性中(4.04至17.33升/小时·千克)比女性中(4.49至10.21升/小时·千克)更显著(标准误均值0.72)(P<0.01)。西咪替丁预处理后,任何维拉帕米处置参数均无显著变化。血浆中维拉帕米的未结合分数为0.157(标准误均值0.001,n = 40)。随着维拉帕米浓度增加(25 - 250微克/升)或加入磺吡酮(50 - 500毫克/升)或西咪替丁(0.5 - 5毫克/升),维拉帕米的血浆蛋白结合无改变。结果表明,磺吡酮诱导(±)-维拉帕米的代谢清除,且反应存在性别差异。(摘要截短至250字)

相似文献

1
Verapamil disposition--effects of sulphinpyrazone and cimetidine.
Br J Clin Pharmacol. 1985 Mar;19(3):385-91. doi: 10.1111/j.1365-2125.1985.tb02658.x.
2
Effect of cimetidine on verapamil disposition.
Clin Pharmacol Ther. 1985 Jun;37(6):654-7. doi: 10.1038/clpt.1985.106.
3
Lack of interaction between verapamil and cimetidine.
Clin Pharmacol Ther. 1985 Sep;38(3):342-9. doi: 10.1038/clpt.1985.183.
5
Influence of cimetidine on verapamil kinetics and dynamics.
Clin Pharmacol Ther. 1984 Oct;36(4):551-4. doi: 10.1038/clpt.1984.218.
6
The influence of cimetidine on the pharmacokinetics of the enantiomers of verapamil in the dog during multiple oral dosing.
J Vet Pharmacol Ther. 1995 Apr;18(2):117-23. doi: 10.1111/j.1365-2885.1995.tb00564.x.
10
Lidocaine disposition--sex differences and effects of cimetidine.
Clin Pharmacol Ther. 1984 May;35(5):695-701. doi: 10.1038/clpt.1984.97.

引用本文的文献

3
Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study.
Toxicol In Vitro. 2019 Oct;60:212-228. doi: 10.1016/j.tiv.2019.05.019. Epub 2019 May 31.
4
Calcium antagonists. Drug interactions of clinical significance.
Drug Saf. 1995 Sep;13(3):157-87. doi: 10.2165/00002018-199513030-00003.
5
Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.
Clin Pharmacokinet. 1986 Nov-Dec;11(6):425-49. doi: 10.2165/00003088-198611060-00002.
6
Selective inhibitory effects of nifedipine and verapamil on oxidative metabolism: effects on theophylline.
Br J Clin Pharmacol. 1988 Mar;25(3):397-400. doi: 10.1111/j.1365-2125.1988.tb03319.x.
8
Pharmacokinetic interactions of cimetidine 1987.
Clin Pharmacokinet. 1987 May;12(5):321-66. doi: 10.2165/00003088-198712050-00002.
9
Adverse reactions and interactions with H2-receptor antagonists.
Med Toxicol. 1986 May-Jun;1(3):192-216. doi: 10.1007/BF03259837.

本文引用的文献

3
Diazepam disposition determinants.
Clin Pharmacol Ther. 1980 Mar;27(3):301-12. doi: 10.1038/clpt.1980.40.
7
Influence of sex and oral contraceptive steroids on antipyrine metabolite formation.
Clin Pharmacol Ther. 1982 Aug;32(2):240-6. doi: 10.1038/clpt.1982.154.
8
The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.
Clin Pharmacol Ther. 1982 Apr;31(4):418-26. doi: 10.1038/clpt.1982.54.
9
Drug interactions with cimetidine.
Clin Pharmacokinet. 1982 Jan-Feb;7(1):23-41. doi: 10.2165/00003088-198207010-00002.
10
Evidence for a dual action of sulphinpyrazone on drug metabolism in man: theophylline-sulphinpyrazone interaction.
Br J Clin Pharmacol. 1983 May;15(5):567-9. doi: 10.1111/j.1365-2125.1983.tb02093.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验